Physician profile
Shannon E Brim
NPI 1659574598
$2,064.86
in general payments reported to CMS, 2019-2025
30 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $244 · 2021: $347 · 2022: $329 · 2023: $332 · 2024: $293 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.69 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Exeltis, USA INC. | $232.12 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $216.52 | 2019-2025 | Veozah |
| Pfizer INC. | $148.84 | 2020-2025 | |
| Organon LLC | $141.41 | 2021-2025 | |
| Novo Nordisk INC | $107.01 | 2021-2023 | Wegovy |
| Biogen, INC. | $87.55 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $82.38 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Daiichi Sankyo INC. | $67.46 | 2019-2024 | Injectafer |
| Optumhealth Care Solutions, LLC | $67.13 | 2023 | Vivify Health Care Team Portal, Zyno Solutions |
| Merck Sharp & Dohme LLC | $58.26 | 2020-2021 | |
| Amgen INC. | $56.49 | 2021-2024 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $55.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.80 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $43.54 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.62 | 2024-2025 | Zepbound |
| Hologic Sales and Service, LLC | $33.57 | 2019-2021 | |
| Lupin INC. | $33.06 | 2020-2021 | |
| Therapeuticsmd, INC. | $29.80 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $19.68 | 2024 | Myfembree |
| Duchesnay USA Incorporated | $18.51 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $18.21 | 2023 | Vivjoa |
| Shield Therapeutics INC | $16.96 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $16.92 | 2021 | |
| Millicent US INC | $16.28 | 2025 | Intrarosa, Femring |
| Mylan Pharmaceuticals INC. | $15.51 | 2019 | |
| Myovant Sciences INC. | $13.75 | 2021 | |
| Allergan, INC. | $11.31 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $10.90 | 2019 | |
| Meditrina | $5.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Brim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.